{"page":{"totalFilteredElements":347},"studies":[{"active":true,"description":"<div>A Phase 3, Randomized, Open-Label Study to Evaluate Safety and Efficacy of Epcoritamab in Combination with R-CHOP Compared to R-CHOP in Subjects with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)</div>","eudractNumber":null,"id":7962,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05578976","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2023-07-20T13:49:14+02:00","shortTitle":"M20-621","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents</div>","eudractNumber":"2021-005725-24","id":7304,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[{"name":"CD (Cluster of Differentiation)","id":"mt_211"},{"name":"CD20","id":"mt_77"}],"nctNumber":"NCT05283720","phase":{"id":"ph_15","name":"Phase IB/II"},"recruitmentStart":"2023-12-19T13:51:13+01:00","shortTitle":"M22-132","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma","eudractNumber":"2021-005587-22","id":7992,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"}],"mutations":[],"nctNumber":"NCT05259839","phase":{"id":"ph_14","name":"Phase I/IB"},"recruitmentStart":"2022-11-09T13:52:09+01:00","shortTitle":"M22-947","therapeutical":true,"therapyLines":[{"id":"tl_2","name":"Zweitlinie"}]},{"active":true,"description":"<div>First-in-Human Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of the BTK Degrader, ABBV-101, in Participants with B-cell Malignancies</div>","eudractNumber":"2023-503594-38","id":8892,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"}],"mutations":[],"nctNumber":"NCT05753501","phase":{"id":"ph_3","name":"Phase I"},"recruitmentStart":"2024-10-25T13:53:15+02:00","shortTitle":"M23-647","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"},{"id":"tl_10","name":"First in Human (FIH) Studie"}]},{"active":true,"description":"Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC): A Database and Biorepository to prospectively collect HCT data, complications and outcomes pertinent \nto graft-versus-host disease from allogeneic HCT patients for future \nanalysis<br />To prospectively collect and store blood for future analysis from allogeneic HCT patients","eudractNumber":null,"id":1727,"indications":[{"id":"leu","name":"Leukämien"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2015-01-27T13:54:30+01:00","shortTitle":"MAGIC adult","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Michigan Acute Graft-versus-Host Disease International Consortium (MAGIC):<br />A Database and Biorepository<br />To prospectively collect HCT data, complications and outcomes pertinent to graft-versus-host disease from allogeneic HCT patients for future analysis<br />To prospectively collect and store blood for future analysis from allogeneic HCT patients.","eudractNumber":null,"id":1326,"indications":[{"id":"sar","name":"Sarkome"},{"id":"sar1","name":"Knochensarkome (Ewing-Sarkom, Osteosarkom etc.)"},{"id":"sar2","name":"Weichteilsarkome (Liposarkom, Leiomyosarkom, etc.)"},{"id":"ped","name":"Kindliche Tumoren (inkl. Gehirntumoren und Leukämien)"},{"id":"ped1","name":"Leukämien"},{"id":"ped4","name":"Weitere solide Tumore"},{"id":"ped5","name":"Weitere Bluterkrankungen / weitere hämatologische Erkrankungen"}],"mutations":[],"nctNumber":null,"phase":null,"recruitmentStart":"2014-10-15T10:55:32+02:00","shortTitle":"MAGIC children","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Studie zur Pr&#228;valenz der Mangelern&#228;hrung bei gastroenterologischen Tumoren und die Auswirkungen einer ern&#228;hrungstherapeutischen Therapie.","eudractNumber":null,"id":11008,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-02-12T12:46:38+01:00","shortTitle":"MALGAT","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Studie der Pr&#228;valenz der Mangelern&#228;hrung bei gastroenterologischen Tumoren und die Auswirkungen einer ern&#228;hrungstherapeutischen Therapie.","eudractNumber":null,"id":11176,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-09-01T09:18:10+02:00","shortTitle":"MALGAT","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Studie der Pr&#228;valenz der Mangelern&#228;hrung bei gastroenterologischen Tumoren und die Auswirkungen einer ern&#228;hrungstherapeutischen Therapie.","eudractNumber":null,"id":11149,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2024-09-01T10:30:08+02:00","shortTitle":"MALGAT","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Studie der Pr&#228;valenz der Mangelern&#228;hrung bei gastroenterologischen Tumoren und die Auswirkungen einer ern&#228;hrungstherapeutischen Therapie.","eudractNumber":null,"id":11415,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2025-07-23T14:02:46+02:00","shortTitle":"MALGAT","therapeutical":false,"therapyLines":[]}]}